Not Yet Recruiting
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
NCT06683755
- Conditions
- Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
- Locations
-
- The University of Texas M. D. Anderson Cancer Center Houston, Texas, United States